Oliveri M B, Palermo R, Mautalen C, Hübscher O
Sección Osteopatías Médicas Médicas, Hospital de Clínicas, Universidad de Buenos Aires, Argentina.
J Rheumatol. 1996 Dec;23(12):2152-5.
An 8-year-old girl with juvenile dermatomyositis (DM) developed dystrophic calcifications 26 months after diagnosis. She also had severe steroid induced bone loss (osteoporosis). The calcifications turned into generalized heterotopic calcinosis with an exoskeleton-like pattern, despite successful treatment of her myopathy with methylprednisolone and immunosuppressive drugs. She was subsequently treated with oral diltiazem (5 mg/kg/day) to control calcinosis and oral pamidronate (4 mg/kg/day) in addition to calcium and vitamin D supplementation, which she had been taking for 3 years. After 21 months of treatment, clinical and radiological examination revealed dramatic regression of the calcinosis. Bone mass reached normal levels, as determined by bone absorptiometry. Diltiazem alone or in combination with other drugs could be a useful therapy in patients with juvenile DM and pronounced calcifications.
一名8岁的幼年皮肌炎(DM)女孩在确诊26个月后出现了营养不良性钙化。她还患有严重的类固醇诱导性骨质流失(骨质疏松症)。尽管使用甲基泼尼松龙和免疫抑制药物成功治疗了她的肌病,但钙化仍发展为全身性异位性钙化,呈现出类似外骨骼的模式。随后,除了她已经服用了3年的钙和维生素D补充剂外,她还接受了口服地尔硫䓬(5毫克/千克/天)以控制钙化,并口服帕米膦酸盐(4毫克/千克/天)。经过21个月的治疗,临床和放射学检查显示钙化显著消退。通过骨吸收测定法确定,骨量达到了正常水平。单独使用地尔硫䓬或与其他药物联合使用可能是治疗患有明显钙化的幼年DM患者的有效疗法。